Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Seizures
Interventions: Survey; Other
Lead sponsor: Vidya Raman; Other
Eligibility: Up to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cystic Fibrosis
Interventions: SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2; Combination Product
Lead sponsor: Spirovant Sciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Kansas City, Kansas • Boston, Massachusetts • New York, New York + 1 more

Conditions: Airway Management, Infant ALL, Children, Only, Endotracheal Intubation
Interventions: Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation, Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation; Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 1 Month to 48 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Cancer
Interventions: celecoxib, epirubicin hydrochloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: etoposide, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 62
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more

Conditions: Chronic Pain, Opioid-Related Disorders
Interventions: Electronic decision support tools, Enhanced patient education materials, Nurse care management, Electronic Patient Registry, Academic detailing; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Rafael, California + 7 more

Conditions: Postoperative Pain, Adverse Effects
Interventions: ISB; Procedure
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: carboplatin, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 91
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Breast Cancer
Interventions: Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Nashville, Tennessee

Conditions: Advanced Cancer
Interventions: Cisplatin, Liposomal Doxorubicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sedentary Behavior, Health Promotion, Overweight and Obesity, Healthy Lifestyle, Diet, Healthy
Interventions: Standard Implementation, Enhanced Implementation; Behavioral
Lead sponsor: Iowa State University; Other
Eligibility: 9 Years to 11 Years
Enrollment: 1,984 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Normal Physiology
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2041
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuromuscular Blockade
Interventions: Sugammadex, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Autism, Autism Spectrum Disorder, Nonverbal Learning Disability
Interventions: Memantine Hydrochloride, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rectal Cancer
Interventions: Eppendorf hypoximeter; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Infertility
Interventions: Menopur, Synarel, HCG trigger, Clomiphene citrate, Letrozole; Drug
Lead sponsor: New Hope Fertility Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 9,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 213
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Triple-Negative Breast Cancer
Interventions: Tiragolumab, Atezolizumab, Nab-paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Birmingham, Alabama • Chicago, Illinois • Charlotte, North Carolina + 2 more

Conditions: Vaccination
Interventions: Girls OnGuard; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Alcohol Use, Unspecified
Interventions: Episodic Future thinking, Volitional choice, Monitoring only; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Renal Disease
Interventions: Sugammadex; Drug
Lead sponsor: Tetsuro Sakai; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obstructive Sleep Apnea
Interventions: Polysomnogram; Procedure
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV/AIDS
Interventions: Family-Based HIV prevention, Adolescent Only Health Promotion; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Revisiting Survey Investigating Why Patients Are Not Receiving Home Anti-convulsant Medication Prior to Surgery/or Procedure Involving General Anesthesia

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Defining the 'Sniffing Position" in Infants and Toddlers - A Pilot Study

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Transforming Opioid Prescribing in Primary Care

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Continuous Interscalene Block Results in Superior Recovery Throughout the First Postoperative Week

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement

SWITCH Implementation Effectiveness Trial

Assessing and Improving Quantitative Magnetic Resonance Imaging Metrics in Human Subjects

Sugammadex as Rescue Therapy

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins

Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females

Behavioral Economic Treatment to Enhance Rural (BETTER) Living

A Pharmacokinetic Study of Sugammadex in Dialysis Patients

Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patients

Project RAP: Family-based HIV Prevention in the Juvenile Drug Court